Zhang et al; “The identification of functional regions of MEK1 using CRISPR tiling screens”; Commun Biol , 2025
Zhang et al; “The identification of functional regions of MEK1 using CRISPR tiling screens”; Commun Biol , 2025
Sharp et al; “Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function”; Nat Commun., 2025
Sharp et al; “Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function”; Nat Commun., 2025
Churcher et al; “Return to Flatland”; Nat Rev Chem., 2025
Churcher et al; “Return to Flatland“; Nat Rev Chem., 2025
Holvey et al; “Fragment-to-Lead Medicinal Chemistry Publications in 2023”; J. Med. Chem., 2025
Holvey et al; “Fragment-to-Lead Medicinal Chemistry Publications in 2023”; J. Med. Chem., 2025
Martins et al; “The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy” Pharmacol Res Perspect, 2024
Martins et al; “The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy” Pharmacol Res Perspect, 2024
https://doi.org/10.1002/prp2.70030
Ramos et al; “Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery” Cell Reports, 2024
Ramos et al; “Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery” Cell Reports, 2024
Palmer et al; “Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase” J Med Chem, 2024
Palmer et al; “Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase” J Med Chem, 2024
Gustavvson et al; “The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1” Science Advances, 2024
Gustavvson et al; “The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1” Science Advances, 2024
Ma et al; “Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor” J. Med. Chem. 2024
Ma et al; “Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor” J. Med. Chem. 2024
Mukherjee, et al; “Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design”; Structure. 2024
Mukherjee, et al; “Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design”; Structure. 2024
© Astex Pharmaceuticals
All rights reserved
